H B Muss

Summary

Affiliation: University of Vermont
Country: USA

Publications

  1. ncbi request reprint Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience
    Hyman B Muss
    University of Vermont, Vermont Cancer Center, Burlington, VT 05405, USA
    J Clin Oncol 25:3699-704. 2007
  2. ncbi request reprint Adjuvant therapy in the elderly: making the right decision
    Hyman B Muss
    University of Vermont and Vermont Cancer Center, Burlington, VT 05401, USA
    J Clin Oncol 25:1870-5. 2007
  3. ncbi request reprint Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen
    Hyman B Muss
    Vermont Cancer Center, University of Vermont College of Medicine, Burlington, Vermont 05401, USA
    Breast J 13:337-45. 2007
  4. ncbi request reprint Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer
    Hyman B Muss
    Fletcher Allen Health Care, Vermont Cancer Center, Burlington, VT 05401, USA
    JAMA 293:1073-81. 2005
  5. ncbi request reprint Adjuvant treatment of elderly breast cancer patients
    H B Muss
    Vermont Cancer Center, University of Vermont College of Medicine, 89 Beaumont Avenue, Given Building E214, Burlington, VT 05405, USA
    Breast 16:S159-65. 2007
  6. doi request reprint Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17
    Hyman B Muss
    University of Vermont College of Medicine, 1 South Prospect St, Saint Joseph 3400, Burlington, VT 05401, USA
    J Clin Oncol 26:1956-64. 2008
  7. doi request reprint Cancer in the elderly: a societal perspective from the United States
    H B Muss
    University of Vermont and Vermont Cancer Center, Hematology Oncology Unit, Burlington, VT 05405, USA
    Clin Oncol (R Coll Radiol) 21:92-8. 2009
  8. pmc Adjuvant chemotherapy in older women with early-stage breast cancer
    Hyman B Muss
    University of Vermont, Burlington, USA
    N Engl J Med 360:2055-65. 2009
  9. ncbi request reprint Adjuvant therapy for older women with breast cancer
    H B Muss
    University of Vermont College of Medicine, Vermont Cancer Center, Burlington, VT 05401, USA
    Breast 12:550-7. 2003
  10. ncbi request reprint Selecting adjuvant endocrine therapy for breast cancer
    Jonathan D Eneman
    Department of Medicine, University of Vermont, Burlington, Vermont, USA
    Oncology (Williston Park) 18:1733-44, discussion 1744-5, 1748, 1751-4. 2004

Detail Information

Publications51

  1. ncbi request reprint Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience
    Hyman B Muss
    University of Vermont, Vermont Cancer Center, Burlington, VT 05405, USA
    J Clin Oncol 25:3699-704. 2007
    ..We compared toxicity of older and younger patients in three randomized trials of adjuvant chemotherapy...
  2. ncbi request reprint Adjuvant therapy in the elderly: making the right decision
    Hyman B Muss
    University of Vermont and Vermont Cancer Center, Burlington, VT 05401, USA
    J Clin Oncol 25:1870-5. 2007
    ..In addition, we discuss the role of comorbidity and how it factors in treatment decisions. Finally, we discuss future research directions and funding for elders with cancer...
  3. ncbi request reprint Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen
    Hyman B Muss
    Vermont Cancer Center, University of Vermont College of Medicine, Burlington, Vermont 05401, USA
    Breast J 13:337-45. 2007
    ..In this trial, HER-2 and CD1 proved of borderline significance as predictive factors for recurrence on tamoxifen. An SVM model that included all clinical and biologic variables correctly predicted relapse in >75% of patients...
  4. ncbi request reprint Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer
    Hyman B Muss
    Fletcher Allen Health Care, Vermont Cancer Center, Burlington, VT 05401, USA
    JAMA 293:1073-81. 2005
    ....
  5. ncbi request reprint Adjuvant treatment of elderly breast cancer patients
    H B Muss
    Vermont Cancer Center, University of Vermont College of Medicine, 89 Beaumont Avenue, Given Building E214, Burlington, VT 05405, USA
    Breast 16:S159-65. 2007
    ..Elders remain under-represented in clinical trials and should be encouraged to participate. Health care providers as well as government leaders and patients need to be educated on cancer in elders...
  6. doi request reprint Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17
    Hyman B Muss
    University of Vermont College of Medicine, 1 South Prospect St, Saint Joseph 3400, Burlington, VT 05401, USA
    J Clin Oncol 26:1956-64. 2008
    ..Breast cancer incidence increases with age and more than 1,300 women age 70 years or older were enrolled onto MA.17, making it ideal to explore the benefits, toxicities, and quality of life (QOL) impact of letrozole on older women...
  7. doi request reprint Cancer in the elderly: a societal perspective from the United States
    H B Muss
    University of Vermont and Vermont Cancer Center, Hematology Oncology Unit, Burlington, VT 05405, USA
    Clin Oncol (R Coll Radiol) 21:92-8. 2009
    ..To meet this challenge we must expand and train the number of health care providers at all levels...
  8. pmc Adjuvant chemotherapy in older women with early-stage breast cancer
    Hyman B Muss
    University of Vermont, Burlington, USA
    N Engl J Med 360:2055-65. 2009
    ..We tested for the noninferiority of capecitabine as compared with standard chemotherapy in women with breast cancer who were 65 years of age or older...
  9. ncbi request reprint Adjuvant therapy for older women with breast cancer
    H B Muss
    University of Vermont College of Medicine, Vermont Cancer Center, Burlington, VT 05401, USA
    Breast 12:550-7. 2003
    ..Ageism is still a barrier to clinical trials participation and clinical trials focusing on older women are needed...
  10. ncbi request reprint Selecting adjuvant endocrine therapy for breast cancer
    Jonathan D Eneman
    Department of Medicine, University of Vermont, Burlington, Vermont, USA
    Oncology (Williston Park) 18:1733-44, discussion 1744-5, 1748, 1751-4. 2004
    ..Finally, four cases illustrating these difficult decisions will be discussed, with recommendations for treatment...
  11. ncbi request reprint Special issues related to breast cancer adjuvant therapy in older women
    S M Witherby
    Vermont Cancer Center, University of Vermont College of Medicine, Burlington, Vermont 05401, USA
    Breast 14:600-11. 2005
    ..Physician education and more clinical trials designed for older women are needed...
  12. ncbi request reprint Managing early-stage breast cancer in your older patients
    Sabrina M Witherby
    Department of Medicine, University of Vermont, College of Medicine, Vermont Cancer Center Burlington, USA
    Oncology (Williston Park) 20:1003-12; discussion 1012-3, 1017-8. 2006
    ..Finally we will discuss the importance of clinical trials in the elderly...
  13. ncbi request reprint Role of adjuvant endocrine therapy in early-stage breast cancer
    H B Muss
    University of Vermont College of Medicine, Fletcher Allen Health Care, Burlington, VT 05401, USA
    Semin Oncol 28:313-21. 2001
    ..Lastly, there is renewed interest in neoadjuvant endocrine therapy, a treatment option that may select those patients with early-stage breast cancer most likely to benefit from endocrine therapy...
  14. doi request reprint Discrepancy between preference and actual adjuvant therapy for breast cancer
    Marie E Wood
    Department of Medicine, University of Vermont, Burlington, VT 05405
    Clin Breast Cancer 10:398-403. 2010
    ..Pretreatment preferences for adjuvant therapy were examined and compared with actual treatment received...
  15. doi request reprint A question of duration: do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy?
    Susan Burdette-Radoux
    Hematology Oncology Unit, University of Vermont and Vermont Cancer Center, Burlington, VT 05405, USA
    Clin Breast Cancer 9:S37-41. 2009
    ..Selection of candidates for extended endocrine therapy should balance recurrence risk, toxicity of treatment, and comorbidities that might impact life expectancy and risk of side effects...
  16. doi request reprint Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer
    Chris E Holmes
    Department of Medicine, University of Vermont, Burlington, Vermont, USA
    Clin Cancer Res 14:3070-6. 2008
    ..We explored the effects of tamoxifen and aromatase inhibitors on concentrations of VEGF and endostatin in plasma, serum, and platelet releasate (induced by platelet activation)...
  17. ncbi request reprint Update in medical oncology for older patients: focus on breast cancer: management of early breast cancer
    S M Witherby
    Department of Medicine, University of Vermont College of Medicine, Vermont Cancer Center, Burlington, Vermont 05401, USA
    Cancer J 11:506-17. 2005
    ..Lastly, we discuss the importance of clinical trials in the elderly and future directions for therapy...
  18. ncbi request reprint Optimizing the use of anthracyclines in the adjuvant treatment of early-stage breast cancer
    Susan Burdette-Radoux
    Department of Medicine, University of Vermont College of Medicine, Burlington, VT 05401, USA
    Clin Breast Cancer 4:264-72. 2003
    ..Ongoing clinical trials should further define the best choice of anthracycline and the optimal dose and schedule of treatment...
  19. ncbi request reprint Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer
    Susan Burdette-Radoux
    Vermont Cancer Center, University of Vermont, Burlington, Vermont 05401, USA
    Breast J 13:274-80. 2007
    ..All four patients receiving neoadjuvant TEC had significant clinical responses (one CR, three PR). No pathologic CRs were seen...
  20. ncbi request reprint Adjuvant chemotherapy in the elderly: whom to treat, what regimen?
    Susan Burdette-Radoux
    Hematology Oncology Unit, University of Vermont, Fletcher Allen Health Care, UHC Campus, St Joseph 3400, One South Prospect Street, Burlington, Vermont 05401, USA
    Oncologist 11:234-42. 2006
    ..Recent data show that most fit elderly patients derive a benefit from standard adjuvant chemotherapy regimens that is equal to that of younger patients...
  21. ncbi request reprint The influence of aging on the early detection, diagnosis, and treatment of breast cancer
    Marisa F Siebel
    Fletcher Allen Health Care, University Health Center, University of Vermont, 1 South Prospect Street, Third Floor, Burlington, VT 05401, USA
    Curr Oncol Rep 7:23-30. 2005
    ..In this review, we evaluate pertinent data and provide guidance for the management of older women with breast cancer...
  22. ncbi request reprint Management of the frail elderly with breast cancer
    Kim Dittus
    University of Vermont, Hematology Oncology Unit, Burlington, Vermont 05405, USA
    Oncology (Williston Park) 21:1727-34; discussion 1737, 1740. 2007
    ..Oncologists need to acquire the skills to appropriately identify frail elders so they select appropriate therapies that will minimize toxicity and maintain quality of life...
  23. ncbi request reprint Clinical research in the older cancer patient
    H B Muss
    Department of Medicine, Vermont Cancer Center, University of Vermont College of Medicine, Burlington, USA
    Hematol Oncol Clin North Am 14:283-91. 2000
    ..Oncologists and geriatricians must work together to guarantee that appropriate funding is made available for cancer research in the elderly population...
  24. ncbi request reprint Diagnosis and treatment of breast cancer in the elderly
    Chris E Holmes
    Department of Medicine, University of Vermont, Burlington, VT, USA
    CA Cancer J Clin 53:227-44. 2003
    ..In addition, the role of screening and new concepts in prevention are discussed with emphasis on the older patient...
  25. ncbi request reprint Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen
    Gretchen G Kimmick
    Wake Forest University School of Medicine, Comprehensive Cancer Center, Wake Forest University, Winston Salem, North Carolina, USA
    Breast J 12:114-22. 2006
    ..Sertraline decreases hot flashes in breast cancer survivors taking tamoxifen and women prefer sertraline to placebo. Further study of sertraline for the management of hot flashes is warranted...
  26. ncbi request reprint Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer
    Kevin S Hughes
    Avon Comprehensive Breast Evaluation Center, Breast Ovarian Cancer Genetics and Risk Assessment Program, Massachusetts General Hospital, Division of Surgical Oncology, Boston 02114, USA
    N Engl J Med 351:971-7. 2004
    ..In women 70 years of age or older who have early breast cancer, it is unclear whether lumpectomy plus tamoxifen is as effective as lumpectomy followed by tamoxifen plus radiation therapy...
  27. ncbi request reprint Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041)
    Gretchen Kimmick
    Comprehensive Cancer Center of Wake Forest University, Winston Salem, NC 27157, USA
    Invest New Drugs 22:83-9. 2004
    ..Good performance status was the most important predictor of survival. In this group of women with metastatic breast cancer, the overall prognosis was poor. This combination of rIL-2 and IFN was ineffective...
  28. pmc Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer
    Judith Anne W Chapman
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, 10 Stuart St, Kingston, ON, Canada
    J Natl Cancer Inst 100:252-60. 2008
    ..We examined factors associated with cause-specific death in a large cohort of breast cancer patients treated with extended adjuvant endocrine therapy...
  29. ncbi request reprint A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    Paul E Goss
    Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    N Engl J Med 349:1793-802. 2003
    ..The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy...
  30. doi request reprint Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen
    Paul E Goss
    Massachusetts General Hospital Cancer Center, 55 Fruit St, Lawrence House, LRH 302, Boston, MA 02114, USA
    J Clin Oncol 26:1948-55. 2008
    ..When the trial was unblinded, patients who received placebo (PLAC) were offered LET...
  31. ncbi request reprint Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 99:295-300. 2006
    ..Analyses were conducted to examine the relationships between duration of treatment on MA.17 and outcomes...
  32. ncbi request reprint Barriers to clinical trial participation by older women with breast cancer
    M Margaret Kemeny
    Cancer and Leukemia Group B and the University ofChicago Medical Center, IL, USA
    J Clin Oncol 21:2268-75. 2003
    ..This study tested whether older patients were offered trials significantly less often than younger patients and whether older patients who were offered trials were more likely to refuse participation than younger patients...
  33. ncbi request reprint Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia
    Marc L Citron
    ProHEALTH Care Associates, LLP, 2800 Marcus Ave, Lake Success, NY 11042, USA
    J Clin Oncol 21:1431-9. 2003
    ....
  34. ncbi request reprint Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
    I Craig Henderson
    University of California at San Francisco, San, Francisco, CA 94143, USA
    J Clin Oncol 21:976-83. 2003
    ..This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival...
  35. ncbi request reprint Long-term follow-up of a phase II trial studying a weekly doxorubicin-based multiple drug adjuvant therapy for stage II node-positive carcinoma of the breast
    Gretchen G Kimmick
    The Comprehensive Cancer Center of Wake Forest University, Winston Salem, NC 27157 1082, USA
    Breast Cancer Res Treat 72:233-43. 2002
    ..This single-arm study aimed to evaluate the effectiveness of an intensive doxorubicin-based multidrug regimen as adjuvant therapy in women with stage II, node positive breast cancer...
  36. ncbi request reprint Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001
    Gretchen G Kimmick
    Duke University Medical Center, Suite 3800 Duke S, Box 3204, Durham, NC 27710, USA
    J Clin Oncol 23:2201-7. 2005
    ..To design and test a geriatric educational intervention to improve accrual of cancer patients age 65 years and older to cooperative group-sponsored treatment trials...
  37. ncbi request reprint Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
    David G Warr
    Princess Margaret Hospital, Medical Oncology, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    J Clin Oncol 23:2822-30. 2005
    ..This is the first study in which the NK(1)-receptor antagonist, aprepitant (APR), was evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy...
  38. ncbi request reprint Optimizing adjuvant chemotherapy in early-stage breast cancer
    Edith Perez
    Multidisciplinary Breast Clinic, Mayo Clinic, Jacksonville, Florida, USA
    Oncology (Williston Park) 19:1759-67; discussion 1768, 1772-4, 1777-8. 2005
    ..Ongoing trials are investigating the efficacy of commonly used regimens, new chemotherapeutic and biologic agents, and novel doses and schedules of currently available agents...
  39. ncbi request reprint Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women
    Timothy J Whelan
    McMaster University, Hamilton, Canada
    J Clin Oncol 23:6931-40. 2005
    ..To evaluate the impact of letrozole compared with placebo after adjuvant tamoxifen on quality of life (QOL) in the MA.17 trial...
  40. pmc Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
    Donald A Berry
    University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    JAMA 295:1658-67. 2006
    ..Breast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy...
  41. ncbi request reprint Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons
    Harold J Burstein
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 7:158-61. 2006
    ..We believe clinicians should be aware of the potential ovarian reserve among women with treatment-related amenorrhea so as to avoid use of AI therapy in patients in whom there is uncertainty about menopausal status...
  42. doi request reprint Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B
    Michael P Digiovanna
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar St, Room WWW 217, New Haven, CT 06510, USA
    J Clin Oncol 26:2364-72. 2008
    ....
  43. ncbi request reprint Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
    Paul E Goss
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Natl Cancer Inst 97:1262-71. 2005
    ..This report presents updated findings from the trial...
  44. ncbi request reprint Targeted therapy for metastatic breast cancer
    Hyman B Muss
    N Engl J Med 355:2783-5. 2006
  45. ncbi request reprint Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
    Paul E Goss
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 25:2006-11. 2007
    ..MA.17 randomized postmenopausal women after 5 years of tamoxifen, to letrozole or placebo. We present outcomes according to tumor receptor status...
  46. ncbi request reprint Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy
    Jørn Herrstedt
    Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark
    Cancer 104:1548-55. 2005
    ..An aprepitant (APR) regimen was evaluated for prevention of nausea and emesis due to moderately emetogenic chemotherapy (MEC) over multiple cycles...
  47. ncbi request reprint American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting
    James L Khatcheressian
    Virginia Commonwealth University Massey Cancer Center, Richmond, VA, USA
    J Clin Oncol 24:5091-7. 2006
    ..To update the 1999 American Society of Clinical Oncology (ASCO) guideline on breast cancer follow-up and management in the adjuvant setting...
  48. ncbi request reprint The cancer and leukemia group B cancer in the elderly committee: addressing a major cancer need
    Harvey Jay Cohen
    Center for the Study of Aging, Duke University Medical Center and Geriatric Research, Education and Clinical Center, Veterans Affairs Medical Center, Durham, North Carolina, USA
    Clin Cancer Res 12:3606s-11s. 2006
    ..The Cancer in the Elderly Committee has been successful in developing, implementing, and completing trials in all these areas and serves as a major resource for clinical trials development for the CALGB...
  49. pmc Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:4109-15. 2008
    ..However, the influence of body mass index (BMI) on the outcome of patients with established colon cancer remains uncertain. Moreover, the impact of change in body habitus after diagnosis has not been studied...
  50. ncbi request reprint Breast cancer in older patients
    Gretchen Kimmick
    Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Semin Oncol 31:234-48. 2004
    ..The goals in treating metastatic breast cancer in an older patient are not different than for younger patients...
  51. pmc High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) st
    Christian Langer
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:5371-9. 2008
    ..We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile...